| Literature DB >> 25918572 |
Fredrick Odhiambo1, Tura Galgalo1, Arvelo Wences1, Onesmus Maina Muchemi1, Evalyne Wambui Kanyina1, Juliana Chepkemoi Tonui2, Samwel Amwayi1, Waqo Boru1.
Abstract
INTRODUCTION: Antimicrobial resistance is neglected in developing countries; associated with limited surveillance and unregulated use of antimicrobials. Consequently, delayed patient recoveries, deaths and further antimicrobial resistance occur. Recent gastroenteritis outbreak at a children's home associated with multidrug resistant non-typhoidal Salmonella spp, raised concerns about the magnitude of the problem in Kenya, prompting antimicrobial resistance assessment preceding surveillance system establishment.Entities:
Keywords: Capacity; antimicrobial resistance; culture; isolates; pattern; practice; susceptibility
Mesh:
Year: 2014 PMID: 25918572 PMCID: PMC4405071 DOI: 10.11604/pamj.2014.19.332.5159
Source DB: PubMed Journal: Pan Afr Med J
Description, practice and capacity of health facilities selected for AMR assessment in Kenya, 2013
| Item | n (%) |
|---|---|
|
| |
| level 6 | 2(25) |
| Level 5 | 4(50) |
| Level 4 | 2(25) |
|
| |
| specimen collection | 5(63) |
| culture processing | 7(88) |
| AST | 5(63) |
|
| |
| Transport Media avail. | 5(63) |
| Media Prep. Room | 6(75) |
| stock TCBS and APW | 6(75) |
| use of McFarland | 5(63) |
|
| |
| V. cholera | 6(75) |
| E. coli | 0(0) |
| Shigella | 2(25) |
| Salmonella | 4(50) |
|
| |
| Archiving system avail | 1(13) |
| TAT sample processing (2hrs) | 4(50) |
| Service contract avail | 0(0) |
| adherence to CLSI | 2(25) |
|
| |
| Not using lab. Results | 8(80) |
| Delay of results | 3(30) |
| No feedback | 5(50) |
| Limited Lab operation hrs | 2(20) |
| AST drug absent in hosp. pharm | 10(100) |
Note: AST, Antimicrobial susceptibility testing; n, Frequency;%, Percent; Prep, Preparation; TCBS, Thiosulfate Citrate Bile Salts sucrose agar; APW, Alkaline peptone water; Avail, Available; V. cholerae, Vibrio cholerae; E.coli, Escherichia coli; TAT, Turnaround time; hrs., hours; CLSI, Clinical and laboratory standards institute; lab., laboratory; hosp., hospital; Pharm, Pharmacy
Enteric bacterial agents isolated from stool and blood culture as reported in the eight assessed laboratories in Kenya, 2013
| Stool | Blood | |
|---|---|---|
| Organism | n (%) | n (%) |
| No pathogen | 4170(84) | 4188(98) |
| E.coli | 617(12) | 31(<1) |
|
| ||
|
| 49(<1) | 12(<1) |
|
| 13(<1) | 7(<1) |
|
| 3(<1) | 0 |
|
| ||
|
| 34(<1) | 0 |
|
| 24(<1) | 0 |
|
| 30(<1) | 0 |
|
| 5(<1) | 0 |
|
| 12(<1) | 0 |
|
| ||
|
| 0 | 7(<1) |
|
| 0 | 2(<1) |
|
| 0 | 1(<1) |
|
| 0 | 1(<1) |
| Others | 34(<1) | 0 |
|
|
|
|
Note: n, Frequency; E. coli, Escherichia coli; spp, species; bact., bacterial; Strept, Streptococcus; <, less than
Isolation rates of enteric pathogenic bacteria agents in the eight assessed laboratories in Kenya, 2013
| Stool culture | Blood culture | |||||
|---|---|---|---|---|---|---|
| Facility | No. tested | No. detected | Detection Rate | No. tested | No. detected | Detection Rate |
| Nat1 | 1,970 | 16 | 1% | 3907 | 58 | 2% |
| Nat2 | 589 | 50 | 9% | 0 | 0 | NT |
| Sub-Nat1 | 534 | 16 | 3% | 42 | 1 | 2% |
| Sub-Nat2 | 191 | 5 | 3% | 309 | 10 | 3% |
| Sub-Nat3 | 951 | 13 | 1% | 0 | 0 | NT |
| Sub-Nat4 | 689 | 62 | 9% | 0 | 0 | NT |
| District1 | 73 | 14 | 19% | 0 | 0 | NT |
| District2 | 0 | 0 | NT | 0 | 0 | 0 |
|
| 4,997 | 176 | 4% | 4258 | 69 | 2% |
Note: No, number; Nat, National; NT, Not tested; Pathogenic bacteria agents, Salmonella and Shigella species
Resistance patterns of enteric pathogens in stool and blood in the eight assessed laboratories to commonly prescribed antimicrobials in Kenya, 2013
| Resistance | |||||||
|---|---|---|---|---|---|---|---|
| Organism | Amp | Tet | Cot | Aug | SMZ | Amox | Cefot |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
|
| 24(90) | 9(76) | 15(91) | 3(100) | 8(73) | 2(100) | 2(50) |
|
| 10(82) | 2(33) | 7(87) | 0(0) | 3(75) | 0(0) | 1(17) |
|
| 6(100) | NT | 2(100) | NT | NT | NT | 3(100) |
|
| 0(0) | 0(0) | 5(100) | 5(63) | 1(100) | 5(83.3) | NT |
|
| 8(80) | 5(63) | 2(100) | NT | 7(100) | NT | NT |
|
| 3(75) | 2(67) | NT | NT | 4(100) | NT | NT |
|
| 7(78) | 5(71) | 10(100) | 3(75) | 7(100) | 4(80) | NT |
|
| 8(36) | 16(84) | 3(100) | 1(50) | 3(100) | 2(100) | NT |
|
| 26(90) | NT | 3(60) | NT | NT | NT | 21(60) |
Note: n, Frequency; AMP, Ampicillin; Tet, Tetracycline; Cot, Cotrimoxazole; Aug, Augmentin; SMZ, Sulfamethoxazole; Amox, Amoxicillin; Cefot, Cefotaxime; spp, species; NT, Not tested